Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

Aim: Sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy has been demonstrated to improve glycemic control and reduce body weight and fat mass in type 2 diabetes mellitus (T2DM). Here, our aim was to investigate the effects of SGLT2i dapagliflozin-treatment on body muscle mass and muscle fat...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugiyama, Seigo, Jinnouchi, Hideaki, Kurinami, Noboru, Hieshima, Kunio, Yoshida, Akira, Jinnouchi, Katsunori, Nishimura, Hiroyuki, Suzuki, Tomoko, Miyamoto, Fumio, Kajiwara, Keizo, Jinnouchi, Tomio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005223/
https://www.ncbi.nlm.nih.gov/pubmed/29225209
http://dx.doi.org/10.5551/jat.40873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005223/
https://www.ncbi.nlm.nih.gov/pubmed/29225209
http://dx.doi.org/10.5551/jat.40873

Ejemplares similares